欢迎来到齐的研究室
齐宪荣 博士 教授 博士生导师
药剂学系 党支部书记
专业和研究方向: 药剂学
研究领域：1.药物递送系统的构筑、靶向化设计与评价
2.纳米技术与生物技术
电话/传真:(10)-82801584 电子信箱：qixr@bjmu.edu.cn
教育及工作经历
2007.8至今 北京大学药学院 教授
1998.7-2007.7 北京大学药学院 副教授
1993.6-1997.6 日本星药科大学 客座研究员
1993.7-1998.7 北京医科大学药学院 讲师
1987.8-1993.7 北京医科大学药学院 助教
1993.6-1997.3 星药科大学（日本） 药学博士学位
1982.9-1987.7 北京医科大学药学院 理学学士学位
荣誉及奖励
2016年北京大学药学院教学优秀奖
2016年北京大学医学部仲外奖教金
2015年北京大学医学部发明专利奖
2014年中国制剂大会优秀论文一等奖（学生王爱婷）
2014年北京大学优秀博士学位论文指导教师（博士生仰浈臻）
2014年医学部大学生创新实验项目一等奖（学生庞宁）
2014年北京大学优秀共产党员
2013年北京大学优秀博士学位论文指导教师（博士生高玮）
2012年北京大学医学部SCI论文引用奖
2012年教育部“高等学校科学技术奖”-自然科学一等奖（5/10 证书号2012-002）
2011年香港大学荣誉教授（2011.1.1-2013.12.31）
2010年北京大学优秀共产党员
2009年高等学校自然科学一等奖（5/9）
2008年北京大学药学院优秀共产党
2008年香港大学荣誉教授（2008.1.1-2010.12.31）
2007年中国中西医结合学会科学技术一等奖（5/17 证书号20078601A）
2007年药学学报优秀论文奖
2003年教育部科技进步二等奖（3/10 证书号2003-049）
2002年中国药剂学会优秀论文一等奖
2001年北京市科技进步三等奖（1/4 证书号2001-药-3-007-1）
2000年中国高校科技进步二等奖（2/3 证书号2000-64）
1999年中国药学会优秀论文二等奖
1998年第四届北医大国际交流论文三等奖
1996年北京医科大学教学优秀奖
1996年永井国际基金会出版奖
1995年国家教委科技进步二等奖（第7完成人证书号95-189）
主持和参加科研项目情况
1. 教育部留学回国启动基金：含有大豆甾醇和大豆甾醇葡萄糖甙的脂质体作为药物载体的研究主持人1998-2000
2. 国家自然科学基金重大项目：有序高级结构分子聚集体的位点、底物和体系选择性。项目批准号：29992597 PI
3. 国家自然科学基金重点项目：生物降解性高分子载体设计与多肽蛋白药物释药系统。项目批准号：59833140 PI
4. 2003.1-2005.12国家自然科学基金：柴胡皂甙-d肽导向药物防治肾小管间质损伤的研究。项目批准号：30271520 PI
5. 2003.7-2005.12科技部863：生物相容性与可降解的可控载药缓释微球血管栓塞剂的研究，项目批准号：2003AA326020 主持人
6. 2004.1-2006.12国家自然科学基金：配体介导肝实质细胞靶向功能脂质体的构筑和基因导入机理研究，项目批准号：30371265 主持人
7. 2006.1－2007.12国家自然科学基金专项研究课题：大分子药物纳米靶向载体的定向输送系统研究项目批准号：90406024 PI
8. 2007.7.1-2011.12重大科学研究计划项目（973）：导向性纳米载药系统及其在脑部疾病治疗与诊断中的应用基础研究，项目批准号：2007CB935801，PI
9. 2008.1-2010.12国家自然科学基金：发夹式"可活化细胞穿透肽介导肿瘤细胞靶向给药系统研究，项目批准号：30772665 主持人
10. 2008.1-2009.6北京市自然基金：以Survivin为靶点的基因输送系统用于肿瘤治疗，项目批准号：7083111 主持人
11. 2010.1-2012.12国家自然科学基金：多功能纳米载体与靶点细胞相互作用的机制研究。项目批准号：30970785，主持人
12. 2009.7-2011.12 新药创制-北京大学综合大平台-中试平台。参加
13. 2009.7-2011.12 新药创制-新制剂与新释药系统技术平台，参加
14. 2011.1-2013.12博士点基金：可激活多肽修饰的纳米载药系统的构建和抗肿瘤作用研究，”项目批准号：20100001110056，主持人
15. 2012 教育部创新团队：载体给药系统的分子药剂学研究 编号：BMU20110263，PI
16. 2012.1-2015.12 科技部重大新药创制：红花黄酮类提取物微粉化制剂抗帕金森病研究”2012ZX09103201-042，PI
17. 2013.01-2015.12北京市自然科学基金针对siRNA的聚合物的基因和化疗药物载体的设计及对肿瘤治疗效果的评价项目编号：7132113，负责人
18. 2013.01-2016.12 国家自然科学基金：肿瘤细胞靶向和内涵体逃逸的纳米给药系统用于多靶点肿瘤治疗，项目编号：81273454，主持人
19. 2013.1-2017.12国家重点基础研究发展计划：脑部肿瘤系统靶向性纳米药物的构建与表征（课题）编号：973-2013CB932501，PI
20. 2014.1-2016.12博士点基金：配体介导和肿瘤微环境敏感的多功能靶向纳米给药系统及其抗肿瘤作用研究项目编号：20130001110055, 主持人
21. 2015.1-2018.12国家自然科学基金：联合应用肿瘤微环境修复与多靶点智能纳米载药系统提高肿瘤治疗效果项目编号：81473156 主持人
22. 2015-2017 方正基金，治疗恶性肿瘤的仿生纳米药物, 主持人
23. 2017.1-2020.12国家自然科学基金：基于肿瘤微环境修复和治疗的纳米递药系统与肿瘤微环境修复机制研究项目编号：81673365，主持人
发表的部分论文：
1. 2017 Yang, Zhen-zhen; Gao, Wei; Liu, Yu-jie; Pang, Ning; Qi, Xian-rong*. Delivering siRNA and Chemotherapeutic Molecules Across BBB and BTB for Intracranial Glioblastoma Therapy. Molecular Pharmaceutics (2017), 14(4), 1012-1022.
2. 2017 Shi, Nian-Qiu; Qi, Xian-Rong*. Taming the Wildness of "Trojan-Horse" Peptides by Charge-Guided Masking and Protease-Triggered Demasking for the Controlled Delivery of Antitumor Agents. ACS Applied Materials & Interfaces (2017), 9(12), 10519-10529.
3. 2017 De-Sheng Liang, Wen-Jie Zhang, Ai-Ting Wang, Hai-Tao Su, Hai-Jun Zhong, Xian-Rong Qi*. Treating metastatic triple negative breast cancer with CD44 neuropilin dual molecular targets of multifunctional nanoparticles. Biomaterials 137 (2017) 23-36.
4. 2017 Yu-Jie Liu, Ying-Cong Ma, Wen-Jie Zhang, Zhen-Zhen Yang, De-Sheng Liang, Zhi-Fu Wu, Xian-Rong Qi*. Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation. Oncotarget. Oncotarget. 2017; 8:42495-42509.
5. 2017 Yingcong Ma, Yujie Liu, Aning Sun, Yitian Du, Min Ye, Xiaoping Pu, Xianrong Qi*. Intestinal absorption and neuroprotective effects of kaempferol-3-O-rutinoside. RSC Adv., 2017, 7, 31408–31416.
6. 2017 Xin Li, Ning Pang, Ji Li, Xianrong Qi*. Characterization of amphiphilic dendrimer modified PEG-PLA nanoparticles prepared by a double emulsion-solvent evaporation method. J. Chin. Pharm. Sci. 2017, 26 (7), 521–527.
7. 2017 Yi Zhang, Ying Zhan, Ning Pang, Yujie Liu, Shixuan Cheng, Ji Li, Yitian Du, Xianrong Qi*. Preparation, characterization and pharmacokinetics of 10-hydroxycamptothecin nanosuspension. J. Chin. Pharm. Sci. 2017, 26 (8), 574–581.
8. 2016 Hai-Tao Su, Xin Li, De-Sheng Liang, Xian-Rong Qi*. Synthetic low-density lipoprotein (sLDL) selectively delivery paclitaxel to tumor with low systemic toxicity. Oncotarget, 2016，7（32）51535-52。
9. 2015 D.S. Liang, H.T. Su, Y.J. Liu, A.T. Wang, X.R. Qi*. Tumor-specific penetrating peptides-functionalized hyaluronic acid-d-α-tocopheryl succinate based nanoparticles for multi-task delivery to invasive cancers. Biomaterials 2015, 71, 11-23.
10. 2015 W. Gao , T. Meng , N. Shi , H. Zhuang , Z. Yang , X.R. Qi*. Targeting and microenvironment responsive lipid nanocarrier for the enhancement of Targeting and Microenvironment-Responsive Lipid Nanocarrier for the Enhancement of Tumor Cell Recognition and Therapeutic Efficiency. Adv. Healthc. Mater. 2015, 4, 748 –759.
11. 2015 A. Wang, D. Liang, Y. Liu, X.R. Qi*. Roles of ligand and TPGS of micelles in regulating internalization, penetration and accumulation against sensitive or resistant tumor and therapy for multidrug resistant tumors. Biomaterials 2015, 53, 160-172.
12. 2015 D. Dong, W. Gao, Y. Liu, X.R. Qi*. Therapeutic potential of targeted multifunctional nanocomplex co-delivery of siRNA and low-dose doxorubicin in breast cancer. Cancer Letters 2015, 359, 178 –186.
13. 2015 L. Sun, Y.J. Liu, Z.Z. Yang, X.R. Qi*. Tumor specific delivery with redox-1 triggered mesoporous silica nanoparticles inducing neovascularization suppression and vascular normalization. RSC Advances, 2015, 5, 55566-55578.
14. 2015 D.S. Liang, H.T. Su, Y.J Liu, A.T. Wang, X.R. Qi*. Enhance Cancer Cell Recognition and Overcome Drug Resistance Using Hyaluronic Acid and α-Tocopheryl Succinate Based Multifunctional Nanoparticles. Mol. Pharmaceutics, 2015, 12 (6), 2189 –2202.
15. 2014 Z.Z. Yang, J.Q. Li, Z.Z. Wang, D.W. Dong, X.R. Qi*. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials 2014, 35, 5226-5239.
16. 2014 Z. Yang, B. Xiang, D. Dong, Z. Wang, J. Li, X.R. Qi*. Dual receptor-specific peptides modified liposomes as VEGF siRNA vector for tumor-targeting therapy. Current Gene Therapy. 2014, 4,289-299.
17. 2014 N.Q. Shi*, X.R. Qi*, B Xiang, Y Zhang. A survey on“Trojan Horse”peptides Opportunities, issues and controlled entry to“Troy”. J. Control. Release 2014, 194, 53 –70.
18. 2014 K. Wu, Z.Z. Wang, D. Liu, X.R. Qi*. Pharmacokinetics, brain distribution, release and blood–brain barrier transport of Shunaoxin pills. J. Ethnopharmacol. 2014, 151, 1133-1140.
19. 2013 W. Gao, B. Xiang, T. Meng, F. Liu, X.R. Qi *. Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides. Biomaterials. 2013, 34: 4137-4149.
20. 2013 D. Dong, B. Xiang,W. Gao, Z. Yang, J. Li, X.R. Qi *. pH-responsive complexes using prefunctionalized polymers for synchronous delivery of doxorubicin and siRNA to cancer cells. Biomaterials. 2013, 34: 4849-4859.
21. 2013 B Xiang, D Dong, N Shi, W Gao, Z Yang, Y Cui, D Cao, XR Qi*. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer. Biomaterials. 2013, 34: 6976-6991.
22. 2013 D Dong, S Tong, XR Qi*. Comparative studies of polyethylenimine-doxorubicin conjugates with pH-sensitive and pH-insensitive linkers. J. Biomed. Mater. Res. 2013, 101A, 1336-1344.
23. 2013 ZZ Yang, YQ Zhang, ZZ Wang, K Wu, JN Lou, XR Qi*. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. Int. J. Pharm. 2013, 452, 344 –354.
24. 2012 ZZ Yang, ZZ Wang, K Wu, XR Qi*. Tissue Distribution and Pharmacodynamics of Rivastigmine after Intranasal and Intravenous Administration in Rats. Current Alzheimer Res. 2012, 9(3), 315-325.
25. 2012 SW Tong, B Xiang, DW Dong, XR Qi*. Enhanced antitumor efficacy and decreased toxicity by self-associated docetaxel in phospholipid-based micelles. Int. J. Pharm.2012, 434, 413 –419.
26. 2012 NQ Shi, W Gao, B Xiang, XR Qi*. Enhancing cellular uptake of activable cell-penetrating peptide–doxorubicin conjugate by enzymatic cleavage. Int. J. Nanomed.2012, 7, 1613 –1621.
27. ZX Lv, LT Liu, XR Qi*. Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy. Int. J. Nanomed. 2011, 6, 1661-1673.
28. 2011 DX Ma, NQ Shi, XR Qi*. Distinct transduction modes of arginine-rich cell-penetrating peptides for cargo delivery into tumor cells. Int. J. Pharm. 2011, 419 （1-2 ）, 200-208.
29. 2011 W zhao, S Zhuang, XR Qi*. Comparative study of the in vitro and in vivo characteristics of cationic and neutral liposomes. Int. J. Nanomed. 2011, 6, 3087-3098.
30. 2010 王鹏程, 齐宪荣*. 可活化细胞穿膜肽的设计与酶解研究. 药学学报 2010, 45(8), 1048-1051.
31. 2010 马冬旭, 齐宪荣*.不同细胞系对细胞穿透肽的摄取与机制比较. 药学学报2010, 45(9), 1165-1169.
32. 2009 Y Li, XR Qi*, Y Maitani, T Nagai. PEG–PLA diblock copolymer micelle-like nanoparticles as all-trans-retinoic acid carrier: in vitro and in vivo characterizations. Nanotechnology 2009, 20, 055106.
33. 2009 WX Ding, T Izumisawa, Y Hattori, XR Qi, D Kitamoto, Y Maitani. Non-ionic surfactant modified cationic liposomes mediated gene transfection in vitro and in the mouse lung. Biol Pharm Bull 2009, 32(2), 311-315.
34. 2009 WX Ding, Y Hattori, XR Qi, Kitamoto Dai; Y Maitani. Surface properties of lipoplexes modified with mannosylerythritol lipid-A and tween 80 and their cellular association. Chem Pharm Bull 2009, 57(2), 138-143.
35. 2008 HL Ma, XR Qi*, WX Ding, Y Maitani, T Nagai. Magnetic targeting after femoral artery administration and biocompatibility assessment of superparamagnetic iron oxide nanoparticles. J Biomed Mater Res 2008, 84A(3), 598-606.
36. 2008 HL Ma, YF Xu, XR Qi*, Y Maitani, T Nagai. Superparamagnetic iron oxide nanoparticles stabilized by alginate: pharmacokinetics, tissue distribution, and applications in detecting liver cancers. Int J Pharm 2008, 354 (1-2):217 –226.
37. 2007 HL Ma, XR Qi*, Y. Maitani, T. Nagai. Preparation and characterization of superparamagnetic iron oxide nanoparticles stabilized by alginate. Int. J. Pharm. 2007, 333:177 –186.
38. 2007 Y Zhang, XR Qi*, Y Gao, L Wei, Y Maitani, T Nagai. Mechanisms of co-modified liver-targeting liposomes as gene delivery carriers based on cellular uptake and antigens inhibition effect. J Control Release 2007, 117, 281 –290.
39. 2007 WX Ding, XR Qi*, Q Fu, SX Piao. The pharmacokinetics and pharmacodynamics of sterylglucoside-modified liposomes for levonorgestrel delivery via nasal route. Drug Delivery 2007, 14, 101-104.
40. 2007 XR Qi*, Y Yan, XD Ma, TY Li, XY Nie, BB Yang. Development of a local vasodilator delivery system using fibrin glue to prevent arterial graft from spasm. J Biomed Mater Res 2007,82A(1), 139 –144.
41. 2006 L Feng，XR Qi*, XJ Zhou, Y Maitani, SC Wang, Y Jiang, T Nagai. Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. J Control Release 2006, 112(1), 35-42 .
42. 2005 XR Qi*, WW Yan, J Shi. Hepatocytes targeting of cationic liposomes modified with soybean sterylglucoside and polyethylene glycol. World J Gastroenterol 2005, 11(32), 4947-4952.
43. 2005 WX Ding, XR Qi*, P Li, Y Maitani, T Nagai. Cholesteryl hemisuccinate as a membrane stabilizer in dipalmitoylphosphatidylcholine liposomes containing saikosaponin-D. Int J Pharm 2005, 300, 38 –47.
44. 2005 J Shi, WW Yan. XR Qi*, Y Maitani, T Nagai. Characteristics and biodistribution of soybean sterylglucoside and polyethylene glycol-modified cationic liposomes and their complexes with antisense oligodeoxynucleotide. Drug delivery 2005, 12(6), 349-356.
45. 2004 CJ Xiao, XR Qi*, Y Maitani, T Nagai. Sustained-release cisplatin from multivesicular liposomes:potentiation of antitumor efficacy against S180 murine carcinoma. J Pharm Sci 2004, 93(7), 1718-1724.
46. 2003 XR Qi*, MH Liu, HY Liu,Y Maitani, T Nagai. Topical econazole delivery using liposomal gel. STP Pharm Sci 2003, 13(4), 241-245.
47. 1999 SH Hwang, Y Maitani, XR Qi, K Takayama, Tsuneji Nagai. Remote loading of diclofenac, insulin and fluorescein isothiocyanate labeled insulin into liposomes by pH and acetate gradient methods. Int J Pharm 1999, 179, 85-95.
48. 1998 K Shimizu, XR Qi, Y Maitani, M Yoshii, K Kawano, K Takayama, T Nagai. Targeting of soybean-derived sterylglucoside liposomes to liver tumors in rat and mice models. Biol Pharm Bull 1998, 21(7), 741-746.
49. 1997 XR Qi, Y Maitani, T Nagai, SL Wei. Comparative pharmacokinetics and antitumor efficacy of doxorubicin encapsulated in soybean-derived sterols and poly(ethylene glycol) liposomes in mice. Int J Pharm 1997,146, 31-39.
50. 1996 XR Qi, Y Maitani, T Nagai. Relation of rigidity of membrane and stability of dipalmitoylphosphatidylcholine liposomes with soybean-derived sterols prepared by reverse-phase evaporation vesicle method. Chem Pharm Bull 1996, 44(1), 237-240.
51. 1995 XR Qi, Y Maitani, T Nagai. Effect of soybean-derived sterols on the in vitro stability and the blood circulation of liposomes in mice. Int J Pharm 1995, 114, 33-41.
52. 1995 XR Qi, Y Maitani, T Nagai. Rates of systemic degradation and reticuloendothelial system uptake of calcein in the dipalmitoylphosphatidylcholine liposomes with soybean-derived sterols in mice. Pharm Res 1995, 12(1), 49-52.
53. 1995 XR Qi, Y Maitani, N Shimoda, K Sakaguchi, T Nagai. Evaluation of liposomal erythropoietin prepared with reverse-phase evaporation vesicle method by subcutaneous administration in rats. Chem Pharm Bul 1995, 43(2), 295-299.
54.1995 Y Maitani, M Hazama, H Tojo, XR Qi, T Nagai. Effects of orally administered liposomes with soybean-derived sterols and their glucosides on rat body weight. Biol Pharm Bull 1995, 18(11), 1551-1555.
